[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"medication-safety\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:medication-safety":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,87,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100648287","air-in-line-alarms-during-antineoplastic-drug-infusion-100648287",false,"NCT07718711","Air-in-Line Alarms During Antineoplastic Drug Infusion","Innovation in Antineoplastic Drug Infusion: A Multiphase Observational Study of Air-in-Line Alarms, Safety, and Therapeutic Continuity","AIR-ONC","Inclusion Criteria:\n\n* Healthcare professionals involved in the administration of antineoplastic drugs in participating oncology centres.\n* Employment in a participating study site during the study period.\n* Direct involvement in routine intravenous antineoplastic drug infusion procedures.\n* Participation in infusion procedures eligible for observation according to the study protocol.\n\nExclusion Criteria:\n\n* Healthcare professionals not directly involved in antineoplastic drug administration.\n* Healthcare professionals working outside participating study sites.\n* Temporary staff not routinely involved in infusion activities during the observation period.\n* Refusal to participate in study activities where local regulations require participant notification.","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate infusion alarms, particularly air-in-line alarms, during antineoplastic drug infusion in oncology care settings.\n\nThe main questions it aims to answer are:\n\nHow frequently do infusion alarms occur, and what types of alarms are observed during antineoplastic drug infusion? How long does it take healthcare professionals to manage infusion alarms and restore infusion continuity? What strategies do healthcare professionals use to manage infusion alarms? How do healthcare professionals evaluate the user experience of different infusion technologies?\n\nParticipants will be healthcare professionals involved in antineoplastic drug infusion. They will not receive any experimental intervention. Researchers will observe routine infusion procedures and collect data on alarm events, alarm management, infusion technologies, and user experience.",[25,26,27,28],"Infusion Safety","Medication Safety","Antineoplastic Drug Administration","Air-in-Line Alarm",[30,31,32,33,34,35,36,37,38],"Antineoplastic agents","Infusion pumps","Air-in-line alarms","Oncology nursing","High-alert medications","User experience","Infusion safety","Alarm management","Entrustable Professional Activities","NOT_YET_RECRUITING","2026-07-16",{"date":42,"type":43},"2026-07-22","ACTUAL",{"date":45,"type":21},"2026-07-01",{"date":47,"type":21},"2028-06-01",{"name":49,"class":50},"Associazione Italiana Infermieri di Area Oncologica","OTHER",5,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":62,"conditions":63,"keywords":69,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100621718","do-qt-prolonging-drugs-cause-major-adverse-cardiac-events-in-hospitalized-adults-100621718","NCT07374263","Do QT-Prolonging Drugs Cause Major Adverse Cardiac Events in Hospitalized Adults?","Do 'Known' QT-prolonging Medications Cause Major Adverse Cardiac Events in Hospitalized Adults? The QTP-MACE Study","QTP-MACE","Inclusion Criteria:\n\n* Adult patients 18 years of age or older\n* Admitted to St. Joseph's Healthcare Hamilton or GEMINI hospitals between December 2017 and March 2025\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years old\n* Outpatient encounters",{"count":61,"type":21},990000,"There are 28 non-cardiology medications from multiple families costing more than $13 billion annually in Canada, categorized as 'Known' QT-prolonging medications (QTPmeds) based on very low levels of evidence. The association between many commonly used medications listed as known QTPmeds and actual major adverse cardiac events (MACE) is weak. Meanwhile, QTPmeds-related warnings are ubiquitous in every healthcare setting, triggering 'hard stop' disruption millions of times per day to front line clinicians. Poor quality medication safety alerts are increasingly recognized as a source of inferior patient care and provider burnout which detracts from healthcare sustainability.\n\nIn this study, anonymized hospital electronic medical record data from more than 990,000 adult patients across Ontario will be used to compare patients who experience MACE with those who do not, measuring their real-time exposure to QT-prolonging drugs. Additionally, machine-learning techniques will also be used to find which patient or treatment factors best predict risk.\n\nThe objectives of this study are to 1) Investigate whether exposure to one or more 'Known' QTPmed is associated with an increased risk of MACE after adjusting for confounders; and 2) Identify predictors and their relative importance for QTPmeds-associated MACE.\n\nIn summary, QT-prolonging medications have the potential to cause very serious adverse events, including death. However, it is not sufficiently clear which patients under which circumstances suffer events, or when is QT prolongation a useful surrogate marker for harm. Meanwhile, ubiquitous medication alerts related to QT-prolonging medications are at best imprecise and at worst, misleading, costly and potentially dangerous. Now that data resources are available with the data elements, structure and sample size required to rigorously assess this association, this study will address this question to improve patient safety, provider satisfaction and the cost-effectiveness of care.",[64,65,66,67,26,68],"Acquired Long QT","Ventricular Arrhythmias","Torsades de Pointes","Syncope","MACE",[70,71,72,73,74,75],"Medication safety","QT interval prolongation","Long QT syndrome","Ventricular arrhythmia","Torsades de pointes","Major adverse cardiac events","RECRUITING","2026-01-24",{"date":79,"type":43},"2026-01-28",{"date":81,"type":43},"2025-02-01",{"date":83,"type":21},"2027-12",{"name":85,"class":50},"St. Joseph's Healthcare Hamilton",2,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":96,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":99,"conditions":100,"keywords":105,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100619599","medicines-in-breast-milk-and-estimated-infant-exposure-100619599","NCT07346716","Medicines in Breast Milk and Estimated Infant Exposure","Medication Concentrations in Human Milk (MedMilk) and Potential Adverse Effects in Breastfed Infants: an Exploratory Clinical Study","MedMilk","Inclusion Criteria:\n\n* Lactating women aged ≥18 years\n* Current use of one or more prescription or over-the-counter (classified within the ATC system) drugs\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Current pregnancy during sample collection\n* Known and clinically significant pharmacokinetic drug-drug interactions at the time of sampling",true,"FEMALE",{"count":98,"type":21},250,"The MedMilk (Medication concentrations in human Milk) study investigates how selected medicines taken by breastfeeding women are transferred into human milk and whether this may affect the breastfed child. The study includes breastfeeding women who are already using prescription or over-the-counter medicines as part of their usual care. Participants provide samples of breast milk and urine and complete a questionnaire about maternal and infant health. The collected data will be used to quantify medicine concentrations in milk and estimate the relative infant dose. The study aims to contribute new data to support safer prescribing and more informed counselling during breastfeeding",[101,26,102,103,104],"Breastfeeding","Lactation","Drug Exposure Via Breast Milk","Pharmacokinetic Parameters",[106,107,108,109],"breastfeeding","lactation","drug transfer into breast milk","medication safety","2026-01-07",{"date":112,"type":43},"2026-01-16",{"date":114,"type":43},"2024-12-20",{"date":116,"type":21},"2030-01",{"name":118,"class":50},"University Hospital Bispebjerg and Frederiksberg",3,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":129,"phases":130,"briefSummary":132,"conditions":133,"keywords":139,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100537125","evaluation-of-medication-management-service-100537125","NCT06273761","Evaluation of Medication Management Service","Primary Care Community Pharmacy Project: Evaluation of Medication Management Service","Inclusion Criteria:\n\n* aged 18 years or above\n* diagnosed with Type 2 diabetes mellitus and\u002For hypertension\n* having regular follow-up on Type 2 diabetes mellitus and\u002For hypertension at Hospital Authority\n* no A\\&E admission\u002Fhospitalization in the past 3 months\n* no recent changes in medication regimen in the past 3 months\n* polypharmacy (taking 5 or more chronic medications)\n* using at least 1 high-risk medication (Anticoagulants, Oral hypoglycaemics, Insulins, psychotropic medications or immunosuppressants)\n* able to communicate in Cantonese and\u002For English\n\nExclusion Criteria:\n\n* aged below 18\n* unable to give informed consent\n* unable to communicate in Cantonese and\u002For English",{"count":128,"type":21},640,"INTERVENTIONAL",[131],"NA","Medication management services (MMS) is a pharmacist-led service of optimizing the medication use and health outcomes, by promoting medication safety and enhancing the ability in self-management of health and diseases of patients and their caregivers. Yet, only limited evidence on the implementation of MMS service in Hong Kong is available. The goal of this clinical trial is to evaluate the cost effectiveness and effects of implementing MMS in community pharmacies owned by 8 non-government organizations (NGOs) in Hong Kong on humanistic and clinical outcomes in patients with hypertension and\u002For type II diabetes mellitus. The clinical trial aims to look into the following aspects:\n\n* To evaluate the perception and satisfaction of patients on MMS service\n* To investigate whether MMS could improve patients' adherence to their medication regimen, health-related quality of life, health outcomes and health service utilization, as well as their ability to understand and cope with their illness and drug-related problems\n* To identify and categorize the types of drug-related problems identified during MMS\n* To evaluate the cost-effectiveness of implementing MMS in community pharmacies\n\nMMS services will be rolled out in a total of 8 NGO community pharmacies progressively (2 pharmacies per phase) in 4 successive phases. Participants will complete the questionnaires at the following time points throughout the trial, namely 1) during recruitment, 2) baseline (1 month before MMS), 3) 3 months after MMS begins, 4) 12 months after MMS begins, and 5) 24 months after MMS begins. Researchers will compare the results of questionnaires conducted at different time points to identify the potential changes in the effects of MMS. Furthermore, researchers will link up the electronic health records of the participants and identify the potential changes in the health outcomes and health service utilizations after receiving MMS.",[134,26,135,136,137,138],"Medication Adherence","Diabetes Mellitus, Type 2","Hypertension","Polypharmacy","High Risk Medications",[140,141],"Medication Management Service","Community pharmacy service","2024-02-21",{"date":144,"type":43},"2024-02-23",{"date":146,"type":43},"2024-02-06",{"date":148,"type":21},"2027-05-01",{"name":150,"class":50},"The University of Hong Kong",8]